Prognostic value of microRNA expression levels in pancreatic adenocarcinoma: a review of the literature.
Prognostic value of microRNA expression levels in pancreatic adenocarcinoma: a review of the literature.
复制标题
DOI：
10.18632/oncotarget.20277
复制
发表时间：
2017-09-22
期刊：
影响因子：
--
通讯作者：
Williams TM
中科院分区：
文献类型：
--
作者：
Wald P;Liu XS;Pettit C;Dillhoff M;Manilchuk A;Schmidt C;Wuthrick E;Chen W;Williams TM
临床和病理指标的预后和失败模式有助于指导临床医生选择胰腺癌(PDAC)手术切除后的辅助治疗。最近的研究已经报道了microRNA图谱在许多恶性肿瘤中的预后作用。在这里，我们回顾和总结目前关于微RNA表达与PDAC患者总存活率之间的关系的文献。我们在PubMed数据库中进行了系统搜索，以确定所有报告肿瘤和/或血清microRNA表达与PDAC患者总存活率之间的预后关联的主要研究研究。作者对符合条件的文章进行了审查，相关研究结果总结如下。我们找到了53种符合我们搜索标准的出版物。总体而言，23个上调的miRNAs和49个下调的miRNAs与较差的总体存活率相关。MiR-21是最常见的miRNA，出现在19篇文献中，所有文献都报道了PDAC中异常过表达并与较短的生存期相关。出现在多个出版物中的其他miRNA包括MIR-10b、−21、−34a、−155、−196a、−198、−200C、−203、−210、−218、−222和−328。我们总结了这些miRNAs在不同的分子信号通路和细胞功能中的临床前和临床数据。越来越多的证据表明，miRNA表达谱具有提供肿瘤特异性预后信息的潜力，以帮助临床医生更恰当地选择患者进行辅助治疗。这些分子经常在PDAC中异常表达，并表现出致癌和/或肿瘤抑制功能。有必要进一步努力开发预测和预测分子标记，并进一步阐明miRNA的作用机制。
Clinical and pathologic markers of prognosis and patterns of failure help guide clinicians in selecting patients for adjuvant therapy after surgical resection for pancreatic adenocarcinoma (PDAC). Recent studies have reported the prognostic utility of microRNA profiling in numerous malignancies. Here, we review and summarize the current literature regarding associations between microRNA expression and overall survival in PDAC patients. We conducted a systematic search in the PubMed database to identify all primary research studies reporting prognostic associations between tumor and/or serum microRNA expression and overall survival in PDAC patients. Eligible articles were reviewed by the authors and relevant findings are summarized below. We found 53 publications that fit our search criteria. In total, 23 up-regulated and 49 down-regulated miRNAs have been associated with worse overall survival. MiR-21 is the most commonly reported miRNA, appearing in 19 publications, all of which report aberrant over-expression and association with shorter survival in PDAC. Other miRNAs that appear in multiple publications include miR-10b, −21, −34a, −155, −196a, −198, −200c, −203, −210, −218, −222, and −328. We summarize the preclinical and clinical data implicating these miRNAs in various molecular signaling pathways and cellular functions. There is growing evidence that miRNA expression profiles have the potential to provide tumor-specific prognostic information to assist clinicians in more appropriately selecting patients for adjuvant therapy. These molecules are often aberrantly expressed and exhibit oncogenic and/or tumor suppressor functions in PDAC. Additional efforts to develop prognostic and predictive molecular signatures, and further elucidate miRNA mechanisms of action, are warranted.
登录
查看更多内容
胰腺癌细胞增殖过程中 miR-26a 介导的细胞周期蛋白 E2 转录后调控的丧失和患者生存率下降
影响因子：
3.7
作者：
Deng J;He M;Chen L;Chen C;Zheng J;Cai Z
通讯作者：
Cai Z
microRNA miR-34抑制人类胰腺癌肿瘤发射细胞。
影响因子：
3.7
作者：
Ji Q;Hao X;Zhang M;Tang W;Yang M;Li L;Xiang D;Desano JT;Bommer GT;Fan D;Fearon ER;Lawrence TS;Xu L
通讯作者：
Xu L
影响因子：
29.4
作者：
Frampton, Adam E.;Castellano, Leandro;Jiao, Long R.
通讯作者：
Jiao, Long R.
影响因子：
--
作者：
Chen M;Wang M;Xu S;Guo X;Jiang J
通讯作者：
Jiang J
影响因子：
9
作者：
Klinkenbijl, JH;Jeekel, J;Wils, J
通讯作者：
Wils, J